Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Foam Versus Placebo for Prevention of Acute Radiation Proctitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Men aged at least 18 years,~* Patients with ECOG performance status \<= 2 or Karnofsky Performance Status Scale \>= 70%,~* Estimated life expectancy more than 3 years,~* Diagnosis of prostate carcinoma,~* Indication for local RT in patients with prostatic cancer.~Exclusion Criteria:~* Crohn's disease, indeterminate colitis, ulcerative colitis, microscopic colitis (i.e., collagenous colitis and lymphocytic colitis),~* Severe or symptomatic ischaemic colitis at baseline,~* Grade III internal haemorrhoids at baseline,~* High risk patients needing extended radiation therapy,~* Acute EORTC/RTOG lower GI toxicity score of \>=1 at baseline,~* Bacterial, amoebic, fungal, or viral infections of the gut,~* Tuberculosis, hypertension, infection, diabetes mellitus (included familiarly predisposition), active peptic ulcer, osteoporosis, glaucoma, or cataract, if careful medical monitoring is not ensured,~* Portal hypertension or liver cirrhosis,~* Abnormal hepatic function (ALT, AST or AP \> 2.5 x ULN),~* Known intolerance/hypersensitivity/resistance to study drug or drugs of similar chemical structure or pharmacological profile, or to any of the other constituents of the study drug,~* Participation in another clinical trial within the last 30 days, simultaneous participation in another clinical trial, or previous participation in this trial

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 2mg rectal budesonide per day for 8 weeks
- 2 (Type: PLACEBO_COMPARATOR): One application of placebo foam once daily for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).